Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis
Introduction
Peritoneal carcinomatosis (PC) is a common evolution of abdominal cancers and is associated with a poor prognosis in the absence of aggressive multimodal therapeutic approaches [1]. Since its origin in the 1990's, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been increasingly used as a curative treatment for PC [2], [3]. CRS and HIPEC offer the best outcome for pseudomyxoma peritonei and mesothelioma [4], [5] and represent the only current curative treatment for colorectal and gastric PC [6], [7]. For non-resectable PC, systemic chemotherapy is the only with limited effect on survival. With modern systemic chemotherapies associated with targeted therapies, expected median survival reaches 20 months for colorectal cancer [8], 17.6 months for ovarian cancer [9], 7 months for gastric cancer [10], and less than 12 months for peritoneal mesothelioma [11].
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is an innovative intraperitoneal chemotherapy approach that seems to enhance the effect of chemotherapy by taking advantage of the physical properties of aerosol and pressure [12]. PIPAC is reported to be safe and well tolerated, with no postoperative hepatic and renal toxicities [13], [14], [15], [16], [17]. The first evidence for the efficacy of PIPAC was promising and reported regression of PC in tumors resistant to systemic chemotherapy [12]. In recent Systematic review, median survival after PIPAC was 13.4–15.4 months for gastric, 11–14.1 months for ovarian, and 15.7 months for colorectal PC [16].
The aim of the present study was to analyze and report the initial experience of PIPAC in three experienced centers in the management of PC who began a PIPAC program in regard to feasibility and postoperative outcome.
Section snippets
Study design
A prospectively maintained multi-institutional peritoneal carcinomatosis database was queried to identify all patients who underwent PIPAC, between December 2015 and December 2016, for non-resectable PC in 3 French tertiary university hospitals experienced in PC management (Lyon Sud university hospital, Clermont-Ferrand university hospital and Montpellier Institute of Cancer). All centers follow the implantation training program for practical and safety procedures organized by Professor Reymond
Results
Seventy-three patients underwent PIPAC for non-resectable PC in the three expert centers (Table 1). The origins of the PC were colorectal, gastric, ovarian, malignant mesothelioma, pseudomyxoma peritonei or other for 20, 26, 13, 8, 1 and 5 patients, respectively. Before the first PIPAC cycle, 57 patients presented symptoms of PC (pain: 33; ascites: 35; transit disorders: 11). At the time of the first PIPAC cycle, median PCI was 19 (1–39). For 57 patients, systemic chemotherapy was performed
Discussion
In this retrospective series of 164 PIPAC procedures in 73 patients with initially non resectable PC, ascites and symptoms related to PC were decreased during the PIPAC program where PCI was improved in 64.5% of patients. Meanwhile, grade III and IV (CTCAE v4) postoperative major complications occurred only 9.7% of treated patients.
In the current literature, mortality associated with PIPAC reached up to 8.3% [20] and major complications occurred in 0–37% of patients [16]. This high mortality is
Conclusion
Implementing a PIPAC program with systemic chemotherapy is feasible and is associated with a risk of postoperative morbidity, even in teams highly experienced in PC management and requires a learning curve in patient selection. International consensus is mandatory to determine a standardized PIPAC protocol.
Disclosure
The authors report no conflicts of interest relevant to this article.
Conflict of interest
The authors declare that they have no competing interests.
Author's contribution
All persons who meet authorship criteria are listed as authors, and all authors certify that they have participated sufficiently in the work to take public responsibility for the content, including participation in the concept, design, writing, or revision of the manuscript.
Furthermore, each author certifies that this material or similar material has not been and will not be submitted to or published in any other publication.
Conception and design of the study: 09/12/2015.
End of acquisition of
Acknowledgements
The authors thank Dr. Michèle Vidal, Dr. Amélie Massardier-Pilonchery, Dr. Nicolas Vantard, Marlene Parisot, Nathalie Vocanson, Salima Zouaoui, Cecile Vidal, Sophie Bidault-Marqués and Carine Scata for their contributions to the implementation of the PIPAC approach.
References (25)
- et al.
The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy
Ann Oncol official J Eur Soc Med Oncol
(2012) - et al.
Chemotherapy of advanced gastric cancer
Cancer Treat Rev
(2007) - et al.
Pressurized IntraPeritoneal aerosol chemotherapy - practical aspects
Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol
(2017) - et al.
A new internet tool to report peritoneal malignancy extent. PeRitOneal MalIgnancy Stage Evaluation (PROMISE) application
Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol
(2016) - et al.
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with low-dose cisplatin and doxorubicin in gastric peritoneal metastasis
J Gastrointest Surg Official J Soc Surg Alimentary Tract
(2016) - et al.
Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol
(2015) - et al.
Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: a phase 2 study
Gynecol Oncol
(2015) - et al.
Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study
Cancer
(2000) - et al.
Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer
Seminars Oncol
(1989) - et al.
Intra-Peritoneal Chemo-Hyperthermia (CHIP): a new therapy in the treatment of the peritoneal seedings. Preliminary report
Int Surg
(1991)
Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
J Clin Oncol Official J Am Soc Clin Oncol
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience
J Clin Oncol Official J Am Soc Clin Oncol
Cited by (89)
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in patients with ovarian cancer: A systematic review
2023, European Journal of Surgical OncologyFeasibility and safety of PIPAC combined with additional surgical procedures: PLUS study
2022, European Journal of Surgical OncologyRegional Therapy Approaches for Gastric Cancer with Limited Peritoneal Disease
2024, Journal of Gastrointestinal CancerPIPAC for Gastrointestinal Malignancies
2023, Journal of Clinical Medicine